Soberana Plus

Soberana Plus, technical name FINLAY-FR-1A, is a COVID-19 candidate vaccine produced by the Finlay Institute, a Cuban epidemiological research institute.^[2]

Soberana Plus

A vial of Soberana Plus
Vaccine description
Target	SARS-CoV-2
Vaccine type	Conjugate
Clinical data
Trade names	Pasteur
Other names	FINLAY-FR-1A
Routes of administration	Intramuscular
Legal status
Legal status	Full list of Soberana Plus authorizations
Identifiers
CAS Number	2695520-51-3[1]

Medical uses

It can be used as a third (booster) dose for Soberana 02 vaccine at eight weeks.^[3][4][5] It's also studied as an independent single-dose vaccine.^[2][6][7]

Efficacy

It combined the Soberana 02, the vaccine booster shot shows an efficacy of 91.2%.^[8] The final result of a third dose of Soberana Plus increased the efficacy up to 92.4%.^[9] Efficacy against severe disease and death is 100% for the heterologous three-dose regimen.^[10]

Clinical trials

Booster dose

Further information: Soberana 02 § Clinical trials

Soberana Plus has also been studied as a booster dose for Soberana 02.^[11][12]

Single dose

Clinical trials of single-dose Soberana Plus

Phase	Registration		Number of participants			Age of participants
	ID	Date	Total	Vaccine	Control
I	RPCEC00000349	2021-01-05	30	30	0	18-55 years
IIa	RPCEC00000366	2021-04-09	20	20	0	19-80 years
IIb			430		Placebo-controlled

Authorizations

On 20 August 2021, Cuba approved Soberana Plus as a booster after two doses of Soberana 02.^[13] On 23 September, Cuba approved Soberana Plus for COVID-19 survivors over 19 years old. On 7 December, the authorization was expanded to include COVID-19 survivors from 2 to 18 years old.^[14]

See also

• Soberana 02